MK1775, a Selective Wee1 Inhibitor, Shows Single-Agent Antitumor Activity against Sarcoma CellsJenny Kreahling, Soner Altiok|Molecular Cancer Therapeutics|2011Cited by 122
Wee1 Inhibition by MK-1775 Leads to Tumor Inhibition and Enhances Efficacy of Gemcitabine in Human SarcomasJenny Kreahling, Soner Altiok|PLoS ONE|2013Cited by 89